{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T23:16:46Z","timestamp":1788218206481,"version":"build-2803163510"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":81,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-55378-z","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T09:42:57Z","timestamp":1781257377000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Retrospective case-control study of pre-diagnosis observational and prescription data in Parkinson\u2019s disease"],"prefix":"10.1038","volume":"16","author":[{"given":"Patrick","family":"Doherty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Duty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"issue":"8","key":"55378_CR1","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1136\/jnnp-2019-322338","volume":"91","author":"J Jankovic","year":"2020","unstructured":"Jankovic, J. & Tan, E. K. Parkinson\u2019s disease: etiopathogenesis and treatment. J. Neurol. Neurosurg. Psychiatry. 91 (8), 795\u2013808 (2020).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"1","key":"55378_CR2","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1001\/archneur.59.1.102","volume":"59","author":"H Apaydin","year":"2002","unstructured":"Apaydin, H., Ahlskog, J. E., Parisi, J. E., Boeve, B. F. & Dickson, D. W. Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch. Neurol. 59 (1), 102\u2013112 (2002).","journal-title":"Arch. Neurol."},{"issue":"9","key":"55378_CR3","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1089\/ars.2009.2490","volume":"11","author":"JM Tan","year":"2009","unstructured":"Tan, J. M., Wong, E. S. & Lim, K. L. Protein misfolding and aggregation in Parkinson\u2019s disease. Antioxid. Redox Signal. 11 (9), 2119\u20132134 (2009).","journal-title":"Antioxid. Redox Signal."},{"key":"55378_CR4","doi-asserted-by":"crossref","unstructured":"Pajares, M., A, I. R., Manda, G., Bosca, L. & Cuadrado, A. Inflammation in Parkinson\u2019s Disease: Mechanisms and Therapeutic Implications. Cells 9(7), 1687 (2020).","DOI":"10.3390\/cells9071687"},{"issue":"2","key":"55378_CR5","doi-asserted-by":"publisher","first-page":"103","DOI":"10.5607\/en.2015.24.2.103","volume":"24","author":"HE Moon","year":"2015","unstructured":"Moon, H. E. & Paek, S. H. Mitochondrial Dysfunction in Parkinson\u2019s Disease. Exp. Neurobiol. 24 (2), 103\u2013116 (2015).","journal-title":"Exp. Neurobiol."},{"key":"55378_CR6","doi-asserted-by":"crossref","unstructured":"Day, J. O. & Mullin, S. The Genetics of Parkinson\u2019s Disease and Implications for Clinical Practice. Genes (Basel) 12(7), 1006 (2021).","DOI":"10.3390\/genes12071006"},{"issue":"4","key":"55378_CR7","doi-asserted-by":"publisher","first-page":"e1011407","DOI":"10.1371\/journal.pgen.1011407","volume":"21","author":"A Askarova","year":"2025","unstructured":"Askarova, A., Yaa, R. M., Marzi, S. J. & Nott, A. Genetic risk for neurodegenerative conditions is linked to disease-specific microglial pathways. PLoS Genet. 21 (4), e1011407 (2025).","journal-title":"PLoS Genet."},{"issue":"9","key":"55378_CR8","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.nrl.2012.04.001","volume":"29","author":"J Campdelacreu","year":"2014","unstructured":"Campdelacreu, J. Parkinson disease and Alzheimer disease: environmental risk factors. Neurologia 29 (9), 541\u2013549 (2014).","journal-title":"Neurologia"},{"key":"55378_CR9","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.ibneur.2022.09.007","volume":"13","author":"D Caligiore","year":"2022","unstructured":"Caligiore, D., Giocondo, F. & Silvetti, M. The Neurodegenerative Elderly Syndrome (NES) hypothesis: Alzheimer and Parkinson are two faces of the same disease. IBRO Neurosci. Rep. 13, 330\u2013343 (2022).","journal-title":"IBRO Neurosci. Rep."},{"issue":"3","key":"55378_CR10","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3988\/jcn.2015.11.3.212","volume":"11","author":"T Paillard","year":"2015","unstructured":"Paillard, T., Rolland, Y. & de Souto Barreto, P. Protective Effects of Physical Exercise in Alzheimer\u2019s Disease and Parkinson\u2019s Disease: A Narrative Review. J. Clin. Neurol. 11 (3), 212\u2013219 (2015).","journal-title":"J. Clin. Neurol."},{"issue":"1","key":"55378_CR11","first-page":"CD013856","volume":"1","author":"M Ernst","year":"2023","unstructured":"Ernst, M. et al. Physical exercise for people with Parkinson\u2019s disease: a systematic review and network meta-analysis. Cochrane Database Syst. Rev. 1 (1), CD013856 (2023).","journal-title":"Cochrane Database Syst. Rev."},{"issue":"8","key":"55378_CR12","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s00702-016-1667-6","volume":"124","author":"N Titova","year":"2017","unstructured":"Titova, N., Padmakumar, C., Lewis, S. J. G. & Chaudhuri, K. R. Parkinson\u2019s: a syndrome rather than a disease? J. Neural Transm (Vienna). 124 (8), 907\u2013914 (2017).","journal-title":"J. Neural Transm (Vienna)"},{"issue":"4","key":"55378_CR13","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41582-024-00940-4","volume":"20","author":"AD Korczyn","year":"2024","unstructured":"Korczyn, A. D. & Grinberg, L. T. Is Alzheimer disease a disease? Nat. Rev. Neurol. 20 (4), 245\u2013251 (2024).","journal-title":"Nat. Rev. Neurol."},{"issue":"4","key":"55378_CR14","doi-asserted-by":"publisher","first-page":"e00841","DOI":"10.1002\/prp2.841","volume":"9","author":"EJR Fletcher","year":"2021","unstructured":"Fletcher, E. J. R., Kaminski, T., Williams, G. & Duty, S. Drug repurposing strategies of relevance for Parkinson\u2019s disease. Pharmacol. Res. Perspect. 9 (4), e00841 (2021).","journal-title":"Pharmacol. Res. Perspect."},{"issue":"12","key":"55378_CR15","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/s41582-020-0397-4","volume":"16","author":"C Ballard","year":"2020","unstructured":"Ballard, C. et al. Drug repositioning and repurposing for Alzheimer disease. Nat. Rev. Neurol. 16 (12), 661\u2013673 (2020).","journal-title":"Nat. Rev. Neurol."},{"issue":"6354","key":"55378_CR16","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1126\/science.aaf3934","volume":"357","author":"S Mittal","year":"2017","unstructured":"Mittal, S. et al. beta2-Adrenoreceptor is a regulator of the alpha-synuclein gene driving risk of Parkinson\u2019s disease. Science 357 (6354), 891\u2013898 (2017).","journal-title":"Science"},{"issue":"3","key":"55378_CR17","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1093\/ije\/dyv098","volume":"44","author":"E Herrett","year":"2015","unstructured":"Herrett, E. et al. Data Resource Profile: Clinical Practice Research Datalink (CPRD). Int. J. Epidemiol. 44 (3), 827\u2013836 (2015).","journal-title":"Int. J. Epidemiol."},{"issue":"6","key":"55378_CR18","doi-asserted-by":"publisher","first-page":"e568","DOI":"10.1212\/WNL.0000000000201489","volume":"100","author":"J Huang","year":"2023","unstructured":"Huang, J. et al. Inflammatory Diseases, Inflammatory Biomarkers, and Alzheimer Disease: An Observational Analysis and Mendelian Randomization. Neurology 100 (6), e568\u2013e581 (2023).","journal-title":"Neurology"},{"issue":"1","key":"55378_CR19","doi-asserted-by":"publisher","first-page":"86","DOI":"10.14283\/jpad.2022.8","volume":"9","author":"B Zheng","year":"2022","unstructured":"Zheng, B. et al. Associations of Cardiovascular and Non-Cardiovascular Comorbidities with Dementia Risk in Patients with Diabetes: Results from a Large UK Cohort Study. J. Prev. Alzheimers Dis. 9 (1), 86\u201391 (2022).","journal-title":"J. Prev. Alzheimers Dis."},{"issue":"10","key":"55378_CR20","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1007\/s40264-015-0319-3","volume":"38","author":"P Imfeld","year":"2015","unstructured":"Imfeld, P., Bodmer, M., Jick, S. S. & Meier, C. R. Benzodiazepine Use and Risk of Developing Alzheimer\u2019s Disease or Vascular Dementia: A Case-Control Analysis. Drug Saf. 38 (10), 909\u2013919 (2015).","journal-title":"Drug Saf."},{"key":"55378_CR21","doi-asserted-by":"crossref","unstructured":"Monti, G. et al. GLP-1 Receptor Agonists in Neurodegeneration: Neurovascular Unit in the Spotlight. Cells 11(13), 2023 (2022).","DOI":"10.3390\/cells11132023"},{"key":"55378_CR22","doi-asserted-by":"publisher","first-page":"106550","DOI":"10.1016\/j.phrs.2022.106550","volume":"186","author":"KO Kopp","year":"2022","unstructured":"Kopp, K. O., Glotfelty, E. J., Li, Y. & Greig, N. H. Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment. Pharmacol. Res. 186, 106550 (2022).","journal-title":"Pharmacol. Res."},{"key":"55378_CR23","doi-asserted-by":"crossref","unstructured":"Kalinderi, K., Papaliagkas, V. & Fidani, L. GLP-1 Receptor Agonists: A New Treatment in Parkinson\u2019s Disease. Int J. Mol. Sci 25(7), 3812 (2024).","DOI":"10.3390\/ijms25073812"},{"issue":"13","key":"55378_CR24","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1056\/NEJMoa2312323","volume":"390","author":"WG Meissner","year":"2024","unstructured":"Meissner, W. G. et al. Trial of Lixisenatide in Early Parkinson\u2019s Disease. N Engl. J. Med. 390 (13), 1176\u20131185 (2024).","journal-title":"N Engl. J. Med."},{"key":"55378_CR25","doi-asserted-by":"publisher","first-page":"109952","DOI":"10.1016\/j.neuropharm.2024.109952","volume":"253","author":"C Holscher","year":"2024","unstructured":"Holscher, C. Glucagon-like peptide-1 class drugs show clear protective effects in Parkinson\u2019s and Alzheimer\u2019s disease clinical trials: A revolution in the making? Neuropharmacology 253, 109952 (2024).","journal-title":"Neuropharmacology"},{"issue":"1","key":"55378_CR26","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s13063-019-3259-x","volume":"20","author":"GD Femminella","year":"2019","unstructured":"Femminella, G. D. et al. Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer\u2019s disease: study protocol for a randomised controlled trial (ELAD study). Trials 20 (1), 191 (2019).","journal-title":"Trials"},{"key":"55378_CR27","doi-asserted-by":"crossref","unstructured":"Becht, E. et al. Dimensionality reduction for visualizing single-cell data using UMAP. Nat Biotechnol 37, 38\u201344 (2018).","DOI":"10.1038\/nbt.4314"},{"key":"55378_CR28","doi-asserted-by":"publisher","unstructured":"Williams, G. Pre-Diagnosis Observational and Prescription History Associated with Alzheimer\u2019s Disease Incidence. In: medRxiv, https:\/\/doi.org\/10.1101\/2024.07.17.24310553 (2024).","DOI":"10.1101\/2024.07.17.24310553"},{"issue":"3","key":"55378_CR29","doi-asserted-by":"publisher","first-page":"e209531","DOI":"10.1212\/WNL.0000000000209531","volume":"103","author":"J You","year":"2024","unstructured":"You, J. et al. Prediction of Future Parkinson Disease Using Plasma Proteins Combined With Clinical-Demographic Measures. Neurology 103 (3), e209531 (2024).","journal-title":"Neurology"},{"issue":"1","key":"55378_CR30","doi-asserted-by":"publisher","first-page":"8336","DOI":"10.1038\/s41598-019-44803-1","volume":"9","author":"EJR Fletcher","year":"2019","unstructured":"Fletcher, E. J. R., Jamieson, A. D., Williams, G., Doherty, P. & Duty, S. Targeted repositioning identifies drugs that increase fibroblast growth factor 20 production and protect against 6-hydroxydopamine-induced nigral cell loss in rats. Sci. Rep. 9 (1), 8336 (2019).","journal-title":"Sci. Rep."},{"issue":"5","key":"55378_CR31","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1002\/ana.25341","volume":"84","author":"S Searles Nielsen","year":"2018","unstructured":"Searles Nielsen, S., Gross, A., Camacho-Soto, A., Willis, A. W. & Racette, B. A. beta2-adrenoreceptor medications and risk of Parkinson disease. Ann. Neurol. 84 (5), 683\u2013693 (2018).","journal-title":"Ann. Neurol."},{"key":"55378_CR32","doi-asserted-by":"crossref","unstructured":"Visanji, N. P., O'Neill, M. J. & Duty, S. Nicotine, but neither the \u03b14\u03b22 ligand RJR2403 nor an \u03b17 nAChR subtype selective agonist, protects against a partial 6-hydroxydopamine lesion of the rat median forebrain bundle. Neuropharmacology 51, 506\u2013516 (2006).","DOI":"10.1016\/j.neuropharm.2006.04.015"},{"issue":"11","key":"55378_CR33","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.4103\/1673-5374.259604","volume":"14","author":"BC Das","year":"2019","unstructured":"Das, B. C., Dasgupta, S. & Ray, S. K. Potential therapeutic roles of retinoids for prevention of neuroinflammation and neurodegeneration in Alzheimer\u2019s disease. Neural Regen Res. 14 (11), 1880\u20131892 (2019).","journal-title":"Neural Regen Res."},{"issue":"6","key":"55378_CR34","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1002\/mds.28551","volume":"36","author":"H Chohan","year":"2021","unstructured":"Chohan, H. et al. Type 2 Diabetes as a Determinant of Parkinson\u2019s Disease Risk and Progression. Mov. Disord. 36 (6), 1420\u20131429 (2021).","journal-title":"Mov. Disord"},{"issue":"2","key":"55378_CR35","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1212\/WNL.0000000000005771","volume":"91","author":"E De Pablo-Fernandez","year":"2018","unstructured":"De Pablo-Fernandez, E., Goldacre, R., Pakpoor, J., Noyce, A. J. & Warner, T. T. Association between diabetes and subsequent Parkinson disease: A record-linkage cohort study. Neurology 91 (2), e139\u2013e142 (2018).","journal-title":"Neurology"},{"issue":"8","key":"55378_CR36","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1002\/mds.29122","volume":"37","author":"D Athauda","year":"2022","unstructured":"Athauda, D. et al. The Impact of Type 2 Diabetes in Parkinson\u2019s Disease. Mov. Disord. 37 (8), 1612\u20131623 (2022).","journal-title":"Mov. Disord"},{"issue":"2","key":"55378_CR37","doi-asserted-by":"publisher","first-page":"563","DOI":"10.3233\/JAD-150610","volume":"51","author":"A Pilotto","year":"2016","unstructured":"Pilotto, A. et al. Vascular Risk Factors and Cognition in Parkinson\u2019s Disease. J. Alzheimers Dis. 51 (2), 563\u2013570 (2016).","journal-title":"J. Alzheimers Dis."},{"issue":"4","key":"55378_CR38","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1002\/ana.25564","volume":"86","author":"BR Kummer","year":"2019","unstructured":"Kummer, B. R. et al. Associations between cerebrovascular risk factors and parkinson disease. Ann. Neurol. 86 (4), 572\u2013581 (2019).","journal-title":"Ann. Neurol."},{"issue":"3","key":"55378_CR39","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1002\/ana.25811","volume":"88","author":"DJ Irwin","year":"2020","unstructured":"Irwin, D. J. et al. Evolution of Alzheimer\u2019s Disease Cerebrospinal Fluid Biomarkers in Early Parkinson\u2019s Disease. Ann. Neurol. 88 (3), 574\u2013587 (2020).","journal-title":"Ann. Neurol."},{"issue":"11","key":"55378_CR40","doi-asserted-by":"publisher","first-page":"5461","DOI":"10.1007\/s00415-023-11875-z","volume":"270","author":"Y Mizutani","year":"2023","unstructured":"Mizutani, Y. et al. Associations of Alzheimer\u2019s-related plasma biomarkers with cognitive decline in Parkinson\u2019s disease. J. Neurol. 270 (11), 5461\u20135474 (2023).","journal-title":"J. Neurol."},{"issue":"1","key":"55378_CR41","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3233\/JPD-202323","volume":"11","author":"Y Compta","year":"2021","unstructured":"Compta, Y. & Revesz, T. Neuropathological and Biomarker Findings in Parkinson\u2019s Disease and Alzheimer\u2019s Disease: From Protein Aggregates to Synaptic Dysfunction. J. Parkinsons Dis. 11 (1), 107\u2013121 (2021).","journal-title":"J. Parkinsons Dis."},{"issue":"1","key":"55378_CR42","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/s12974-022-02584-x","volume":"19","author":"RJ Boyd","year":"2022","unstructured":"Boyd, R. J., Avramopoulos, D., Jantzie, L. L. & McCallion, A. S. Neuroinflammation represents a common theme amongst genetic and environmental risk factors for Alzheimer and Parkinson diseases. J. Neuroinflammation. 19 (1), 223 (2022).","journal-title":"J. Neuroinflammation"},{"issue":"3","key":"55378_CR43","doi-asserted-by":"publisher","first-page":"158","DOI":"10.2174\/1874609810666170315113244","volume":"10","author":"JA McKenzie","year":"2017","unstructured":"McKenzie, J. A. et al. Neuroinflammation as a Common Mechanism Associated with the Modifiable Risk Factors for Alzheimer\u2019s and Parkinson\u2019s Diseases. Curr. Aging Sci. 10 (3), 158\u2013176 (2017).","journal-title":"Curr. Aging Sci."},{"issue":"2","key":"55378_CR44","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/alz.12871","volume":"19","author":"A Carey","year":"2023","unstructured":"Carey, A. & Fossati, S. Hypertension and hyperhomocysteinemia as modifiable risk factors for Alzheimer\u2019s disease and dementia: New evidence, potential therapeutic strategies, and biomarkers. Alzheimers Dement. 19 (2), 671\u2013695 (2023).","journal-title":"Alzheimers Dement."},{"issue":"1","key":"55378_CR45","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.jcmg.2020.10.018","volume":"14","author":"GL Burke","year":"2021","unstructured":"Burke, G. L. & Hughes, T. M. Arterial Changes Connecting Hypertension to Alzheimer\u2019s Disease and Related Dementias. JACC Cardiovasc. Imaging. 14 (1), 186\u2013188 (2021).","journal-title":"JACC Cardiovasc. Imaging"},{"issue":"1","key":"55378_CR46","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3233\/JAD-190474","volume":"71","author":"MJ Lennon","year":"2019","unstructured":"Lennon, M. J., Makkar, S. R., Crawford, J. D. & Sachdev, P. S. Midlife Hypertension and Alzheimer\u2019s Disease: A Systematic Review and Meta-Analysis. J. Alzheimers Dis. 71 (1), 307\u2013316 (2019).","journal-title":"J. Alzheimers Dis."},{"issue":"7","key":"55378_CR47","doi-asserted-by":"publisher","first-page":"e815","DOI":"10.1212\/WNL.0000000000010005","volume":"95","author":"JW Kim","year":"2020","unstructured":"Kim, J. W. et al. Serum albumin and beta-amyloid deposition in the human brain. Neurology 95 (7), e815\u2013e826 (2020).","journal-title":"Neurology"},{"key":"55378_CR48","doi-asserted-by":"crossref","unstructured":"Kumar, V., Kim, S. H. & Bishayee, K. Dysfunctional Glucose Metabolism in Alzheimer\u2019s Disease Onset and Potential Pharmacological Interventions. Int J. Mol. Sci 23(17), 9540 (2022).","DOI":"10.3390\/ijms23179540"},{"key":"55378_CR49","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.trci.2018.06.014","volume":"4","author":"JW Kinney","year":"2018","unstructured":"Kinney, J. W. et al. Inflammation as a central mechanism in Alzheimer\u2019s disease. Alzheimers Dement. (N Y). 4, 575\u2013590 (2018).","journal-title":"Alzheimers Dement. (N Y)"},{"issue":"14","key":"55378_CR50","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1001\/jama.2020.11935","volume":"324","author":"C Shufelt","year":"2020","unstructured":"Shufelt, C. & LeVee, A. Hormonal Contraception in Women With Hypertension. JAMA 324 (14), 1451\u20131452 (2020).","journal-title":"JAMA"},{"issue":"5","key":"55378_CR51","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1161\/HYPERTENSIONAHA.122.20018","volume":"80","author":"NA Cameron","year":"2023","unstructured":"Cameron, N. A., Blyler, C. A. & Bello, N. A. Oral Contraceptive Pills and Hypertension: A Review of Current Evidence and Recommendations. Hypertension 80 (5), 924\u2013935 (2023).","journal-title":"Hypertension"},{"key":"55378_CR52","doi-asserted-by":"crossref","unstructured":"Xu, H., Eisenberg, D. L., Madden, T., Secura, G. M. & Peipert, J. F. Medical contraindications in women seeking combined hormonal contraception. Am J Obstet Gynecol 210(3):210 e211-215. (2014).","DOI":"10.1016\/j.ajog.2013.11.023"},{"issue":"9","key":"55378_CR53","doi-asserted-by":"publisher","first-page":"e15267","DOI":"10.14814\/phy2.15267","volume":"10","author":"CZ Kalenga","year":"2022","unstructured":"Kalenga, C. Z. et al. The effect of non-oral hormonal contraceptives on hypertension and blood pressure: A systematic review and meta-analysis. Physiol. Rep. 10 (9), e15267 (2022).","journal-title":"Physiol. Rep."},{"key":"55378_CR54","doi-asserted-by":"crossref","unstructured":"Lauring, J. R., Lehman, E. B., Deimling, T. A., Legro, R. S. & Chuang, C. H. Combined hormonal contraception use in reproductive-age women with contraindications to estrogen use. Am J Obstet Gynecol 215(3):330 e331-337. (2016).","DOI":"10.1016\/j.ajog.2016.03.047"},{"issue":"4\u20135","key":"55378_CR55","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.jsbmb.2009.11.007","volume":"118","author":"LH Coker","year":"2010","unstructured":"Coker, L. H. et al. Postmenopausal hormone therapy and cognitive outcomes: the Women\u2019s Health Initiative Memory Study (WHIMS). J. Steroid Biochem. Mol. Biol. 118 (4\u20135), 304\u2013310 (2010).","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"1","key":"55378_CR56","doi-asserted-by":"publisher","first-page":"e23627","DOI":"10.1002\/jbt.23627","volume":"38","author":"AS Tripathi","year":"2024","unstructured":"Tripathi, A. S. et al. Beneficial effect of 5-HT1b\/1d agonist on Parkinson\u2019s disease by modulating glutamate and reducing deposition of alpha-synuclein. J. Biochem. Mol. Toxicol. 38 (1), e23627 (2024).","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"55378_CR57","doi-asserted-by":"publisher","first-page":"116254","DOI":"10.1016\/j.taap.2022.116254","volume":"454","author":"M Shayan","year":"2022","unstructured":"Shayan, M. et al. Neuroprotective effects of Lasmiditan and Sumatriptan in an experimental model of post-stroke seizure in mice: Higher effects with concurrent opioid receptors or K(ATP) channels inhibitors. Toxicol. Appl. Pharmacol. 454, 116254 (2022).","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"10479","key":"55378_CR58","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/S0140-6736(24)02808-3","volume":"405","author":"N Vijiaratnam","year":"2025","unstructured":"Vijiaratnam, N. et al. Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson\u2019s disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial. Lancet 405 (10479), 627\u2013636 (2025).","journal-title":"Lancet"},{"issue":"6","key":"55378_CR59","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1007\/s12325-022-02153-x","volume":"39","author":"M Jensterle","year":"2022","unstructured":"Jensterle, M., Rizzo, M., Haluzik, M. & Janez, A. Efficacy of GLP-1 RA Approved for Weight Management in Patients With or Without Diabetes: A Narrative Review. Adv. Ther. 39 (6), 2452\u20132467 (2022).","journal-title":"Adv. Ther."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55378-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55378-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55378-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T22:51:44Z","timestamp":1788216704000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55378-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["55378"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-55378-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8947558\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"assertion":[{"value":"23 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Clinical Practice Research Datalink (CPRD) Independent Scientific Advisory Committee (ISAC) for the Medicines and Healthcare products Regulatory Agency (protocol reference: 14_111). The study was conducted in accordance with relevant national guidelines and regulations and adhered to the ethical principles outlined in the Declaration of Helsinki. The study used anonymised routinely collected primary care data obtained under licence from CPRD. As the data were fully anonymised prior to access, individual informed consent was not required. The requirement for patient consent was waived by the CPRD Independent Scientific Advisory Committee (ISAC) in accordance with national data governance regulations.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"27309"}}